SCHEMBL7823845

SCHEMBL7823845

COC(=O)C1CN[C@H](C(=O)OC)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.52
CHRNA4 P43681 2/20 0.52
CHRNB4 P30926 1/20 0.52
CHRNA3 P32297 1/20 0.52
CHRNA7 P36544 1/20 0.52
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP2C19 P33261 1/20 0.47
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
DPP4 P27487 1/20 0.37
BRD4 O60885 1/20 0.35
TP53 P04637 1/20 0.35
KMT2A Q03164 1/20 0.35
CHEK2 O96017 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8481945 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL7823846 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL7491950 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL27970690 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL7491943 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL8481947 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL8482485 1.00 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL7424981 0.88 CYP2D6 (0.64) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL7424991 0.88 CYP2D6 (0.64) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL7424985 0.88 CYP2D6 (0.64) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104276991-B A kind of preparation method of 2 carboxylic acid pyrrolidin derivatives 浙江九洲药物科技有限公司 2018-04-06 CN disclosed
US-9902693-B2 Preparation method for pyrrolidine-2-carboxylic acid derivatives ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2018-02-27 US disclosed
US-9902693-B2 Preparation method for pyrrolidine-2-carboxylic acid derivatives ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2018-02-27 US disclosed
US-9902693-B2 Preparation method for pyrrolidine-2-carboxylic acid derivatives ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2018-02-27 US disclosed
US-20160145208-A1 Preparation method for pyrrolidine-2-carboxylic acid derivatives ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2016-05-26 US disclosed
US-20160145208-A1 Preparation method for pyrrolidine-2-carboxylic acid derivatives ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2016-05-26 US disclosed
US-20160145208-A1 Preparation method for pyrrolidine-2-carboxylic acid derivatives ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2016-05-26 US disclosed
EP-3015456-A1 PREPARATION METHOD FOR PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2016-05-04 EP disclosed
EP-3015456-A1 PREPARATION METHOD FOR PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2016-05-04 EP disclosed
EP-0874849-B1 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO 1,2-A]PYRAZINE DERIVATIVES PFIZER (US) 2001-09-19 EP disclosed
US-6284757-B1 ANTISEROTINONE AGENT PFIZER INC. 2001-09-04 US disclosed
EP-0982030-A2 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands Pfizer Products Inc. (US) 2000-03-01 EP disclosed
US-5942537-A ADMINISTERING A L-TRANS PYRROLIDINE DERIVATIVE TO INHIBIT THE TRANSPORT OF L-GLUTAMATE OR L-ASPARTATE OR AN EXCITATORY AMINO ACID NEUROTRANSMITTER AWAY FROM A SYNAPSE COMPRISING CONTACTING SYNAPSE WITH PYRROLIDINE DERIVATIVE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-08-24 US disclosed
US-5714487-A 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives PFIZER INC. (US) 1998-02-03 US disclosed
EP-0497895-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1992-08-12 EP disclosed
WO-1991006536-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1991-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145208-A1 Preparation method for pyrrolidine-2-carboxylic acid derivatives PDHB, HPD, PYCR1 CHRNB2 3818/4885CHRNA4 4311/4885CHRNB4 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.